Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.
PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.
|Non-melanomatous Skin Cancer||Drug: imiquimod Procedure: conventional surgery||Phase 3|
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Official Title:||A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma|
- Absence of local recurrence at 3 years after start of treatment
- Recurrence of basal cell cancer (BCC) at 1, 2, and 5 years
- Time to first occurrence up to 5 years from completion of study treatment
- Aesthetic appearance of lesion site as measured by participant and blind observer using 5-point Likert scale at 6 months, and then years 1-3
- Pain at lesion site as measured by 6-point scale daily during treatment, and then 16 weeks after the completion of study treatment
- Cost effectiveness assessed up to 3 or 5 years
|Study Start Date:||October 2002|
|Study Completion Date:||April 2010|
- Compare the rate of local recurrence at 3 years in patients with nodular or superficial basal cell skin cancer treated with imiquimod 5% cream vs excisional surgery.
- Compare recurrence at 6 months and 1, 2, and 5 years in patients treated with these regimens.
- Compare the time to first recurrence in patients treated with these regimens.
- Compare the aesthetic appearance of lesion sites in patients treated with these regimens.
- Compare pain in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and lesion type (nodular vs superficial). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive topical imiquimod to a single lesion once daily for 6 weeks for a superficial lesion or 12 weeks for a nodular lesion. Patients with early treatment failure or recurrence are offered surgical excision.
- Arm II: Patients undergo surgical excision. Patients are followed at 6, 12, and 18 weeks, every 6 months for 1 year, annually for 2 years, and then at 5 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study within 18 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00066872
|Chesterfield Royal Hospital|
|Chesterfield, England, United Kingdom, S44 5BL|
|Queen's Medical Centre|
|Nottingham, England, United Kingdom, NG7 2UH|
|Solihull, England, United Kingdom, B91 2JL|
|OverallOfficial:||Mara Ozolins, MS||Queen's Medical Centre|